Corrigendum to “Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study" [Eur Urol 84(5) (2023) 449-454]

Elizabeth R. Plimack, Thomas Powles, Viktor Stus, Rustem Gafanov, Dmitry Nosov, Tom Waddell, Boris Alekseev, Frédéric Pouliot, Bohuslav Melichar, Denis Soulières, Delphine Borchiellini, Raymond S. McDermott, Ihor Vynnychenko, Yen Hwa Chang, Satoshi Tamada, Michael B. Atkins, Chenxiang Li, Rodolfo Perini, L. Rhoda Molife, Jens BedkeBrian I. Rini

Research output: Contribution to journal › Comment/debate

1 Scopus citations

Fingerprint

Dive into the research topics of 'Corrigendum to “Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study" [Eur Urol 84(5) (2023) 449-454]'. Together they form a unique fingerprint.

Nursing and Health Professions

Medicine and Dentistry